Mitchell C. Posner to Combined Modality Therapy
This is a "connection" page, showing publications Mitchell C. Posner has written about Combined Modality Therapy.
Connection Strength
1.135
-
Perioperative Gemcitabine?+?Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Ann Surg Oncol. 2019 Dec; 26(13):4489-4497.
Score: 0.133
-
Adjuvant Therapy Improves Survival for T2N0 Gastric Cancer Patients with Sub-optimal Lymphadenectomy. Ann Surg Oncol. 2016 06; 23(6):1956-62.
Score: 0.104
-
Defining the Benefit of Adjuvant Therapy Following Resection for Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2015 Jul; 22(7):2209-17.
Score: 0.096
-
A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial. Ann Surg Oncol. 2012 Feb; 19(2):384-91.
Score: 0.076
-
Extended follow-up after extended lymphadenectomy for gastric cancer: was it worth the wait? Lancet Oncol. 2010 May; 11(5):404-5.
Score: 0.070
-
Presence of distal intramural spread after preoperative combined-modality therapy for adenocarcinoma of the rectum: what is now the appropriate distal resection margin? Surgery. 2005 Oct; 138(4):658-63; discussion 663-4.
Score: 0.051
-
Non-resective ablation therapy for hepatocellular carcinoma: effectiveness measured by intention-to-treat and dropout from liver transplant waiting list. Clin Transplant. 2004 Oct; 18(5):502-12.
Score: 0.048
-
The role of surgery in the management of oesophageal cancer. Lancet Oncol. 2003 Aug; 4(8):481-8.
Score: 0.044
-
Selective gene expression using a DF3/MUC1 promoter in a human esophageal adenocarcinoma model. Gene Ther. 2003 Feb; 10(3):206-12.
Score: 0.042
-
Combined gene therapy and ionizing radiation is a novel approach to treat human esophageal adenocarcinoma. Ann Surg Oncol. 2002 Jun; 9(5):500-4.
Score: 0.040
-
Hypothyroidism incidence after multimodality treatment for stage III and IV squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys. 2001 Nov 01; 51(3):599-604.
Score: 0.039
-
Complete 5-year follow-up of a prospective phase II trial of preoperative chemoradiotherapy for esophageal cancer. Surgery. 2001 Oct; 130(4):620-6; discussion 626-8.
Score: 0.039
-
Apoptosis in esophageal cancer following induction chemoradiotherapy. J Surg Res. 1998 Sep; 79(1):20-4.
Score: 0.031
-
Preoperative chemoradiotherapy for carcinoma of the esophagus and gastroesophageal junction. Cancer J Sci Am. 1998 Jul-Aug; 4(4):237-46.
Score: 0.031
-
Role of nutrition support during induction chemoradiation therapy in esophageal cancer. JPEN J Parenter Enteral Nutr. 1998 Jan-Feb; 22(1):18-21.
Score: 0.030
-
Is esophagectomy following upfront chemoradiotherapy safe and necessary? Arch Surg. 1997 May; 132(5):481-5; discussion 485-6.
Score: 0.028
-
Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance. Oncotarget. 2016 Jul 12; 7(28):43039-43051.
Score: 0.027
-
Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma. Cancer J Sci Am. 1995 Nov-Dec; 1(4):274-80.
Score: 0.026
-
Processes of care in the multidisciplinary treatment of gastric cancer: results of a RAND/UCLA expert panel. JAMA Surg. 2014 Jan; 149(1):18-25.
Score: 0.023
-
Non-invasive breast carcinoma. Breast Cancer Res Treat. 1992; 21(3):155-64.
Score: 0.020
-
Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial. Ann Surg Oncol. 2011 Feb; 18(2):337-44.
Score: 0.018
-
Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction. Med Oncol. 2011 Dec; 28 Suppl 1:S152-61.
Score: 0.018
-
Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. Ann Oncol. 2011 Feb; 22(2):348-54.
Score: 0.018
-
Gene expression changes in peripheral blood cells provide insight into the biological mechanisms associated with regimen-related toxicities in patients being treated for head and neck cancers. Oral Oncol. 2007 Mar; 43(3):289-300.
Score: 0.014
-
Chemo-inducible gene therapy. Anticancer Drugs. 2005 Nov; 16(10):1053-8.
Score: 0.013
-
Forphenicinol enhances the antitumor effects of cyclophosphamide in a model of squamous cell carcinoma. Cancer Chemother Pharmacol. 2005 Sep; 56(3):317-21.
Score: 0.012
-
Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity. Mol Cancer Ther. 2004 Sep; 3(9):1167-75.
Score: 0.012
-
Dual induction of the Epo-Egr-TNF-alpha- plasmid in hypoxic human colon adenocarcinoma produces tumor growth delay. Am Surg. 2003 Jan; 69(1):24-7.
Score: 0.011
-
Concurrent cis-platinum and radiation with or without surgery for advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 1994 Dec 01; 30(5):1043-50.
Score: 0.006
-
Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. Arch Surg. 1993 May; 128(5):559-64.
Score: 0.005
-
Efficacy of multimodality therapy in gastric adenocarcinoma. Semin Surg Oncol. 1993 Jan-Feb; 9(1):19-26.
Score: 0.005
-
Combined modality therapy for stage IIIA non-small cell carcinoma of the lung. Eur J Cancer. 1993; 29A(4):511-5.
Score: 0.005